[go: up one dir, main page]

TR200201613T2 - Antitümör tesirli 2-(1H-indol-3-il)-2-okso asetamidler - Google Patents

Antitümör tesirli 2-(1H-indol-3-il)-2-okso asetamidler

Info

Publication number
TR200201613T2
TR200201613T2 TR2002/01613T TR200201613T TR200201613T2 TR 200201613 T2 TR200201613 T2 TR 200201613T2 TR 2002/01613 T TR2002/01613 T TR 2002/01613T TR 200201613 T TR200201613 T TR 200201613T TR 200201613 T2 TR200201613 T2 TR 200201613T2
Authority
TR
Turkey
Prior art keywords
acetamides
indol
oxo
antitumor effect
tumors
Prior art date
Application number
TR2002/01613T
Other languages
English (en)
Inventor
Menta Ernesto
Pescalli Nicoletta
Original Assignee
Novuspharma S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novuspharma S.P.A. filed Critical Novuspharma S.P.A.
Publication of TR200201613T2 publication Critical patent/TR200201613T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Yukaridaki formül (I)'in özellikle sert tümörler, daha ayrintili olarak da bagirsak ve akciger tümörleri karsisinda antitümör tesiri sergileyen 2-(1H-indol-3-il)-2-okso-asetamidleri olup, bu formüldeki Y oksijen veya sülfür atomu ve X,R1,R2,R3,R4, ve R5 de istem 1'de tanimlandigi gibidir.
TR2002/01613T 1999-12-23 2000-12-21 Antitümör tesirli 2-(1H-indol-3-il)-2-okso asetamidler TR200201613T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1999MI002693A IT1315267B1 (it) 1999-12-23 1999-12-23 Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale

Publications (1)

Publication Number Publication Date
TR200201613T2 true TR200201613T2 (tr) 2002-10-21

Family

ID=11384182

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/01613T TR200201613T2 (tr) 1999-12-23 2000-12-21 Antitümör tesirli 2-(1H-indol-3-il)-2-okso asetamidler

Country Status (24)

Country Link
US (1) US6753342B2 (tr)
EP (1) EP1244652B1 (tr)
JP (1) JP2003519140A (tr)
KR (1) KR100795533B1 (tr)
CN (1) CN1250542C (tr)
AT (1) ATE302772T1 (tr)
AU (1) AU776332B2 (tr)
BR (1) BR0016553A (tr)
CA (1) CA2395205A1 (tr)
CZ (1) CZ20022170A3 (tr)
DE (1) DE60022227T2 (tr)
EA (1) EA004925B1 (tr)
ES (1) ES2246918T3 (tr)
HU (1) HUP0203524A3 (tr)
IL (2) IL150329A0 (tr)
IT (1) IT1315267B1 (tr)
MX (1) MXPA02006217A (tr)
NO (1) NO323312B1 (tr)
NZ (1) NZ519689A (tr)
PL (1) PL356541A1 (tr)
SK (1) SK285682B6 (tr)
TR (1) TR200201613T2 (tr)
WO (1) WO2001047916A1 (tr)
ZA (1) ZA200204964B (tr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200003130T2 (tr) 1998-04-28 2001-01-22 Arzneimittelwerk Dresden Gmbh Yeni hidroksiindoller, bunların fosfodiesteraz 4 inhibitörleri olarak kullanımları ve hazırlanmaları için işlemler
IT1318641B1 (it) 2000-07-25 2003-08-27 Novuspharma Spa Ammidi di acidi 2-(1h-indol-3-il)-2-oxo-acetici ad attivita'antitumorale.
DE10037310A1 (de) * 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
CA2491802C (en) * 2002-07-09 2012-04-10 Fasgen, Inc. Novel compounds, pharmaceutical compositions containing same, and methods of use for same
MXPA06002853A (es) 2003-09-11 2006-06-14 Kemia Inc Inhibidores citoquina.
BRPI0508579A (pt) * 2004-03-11 2007-08-14 Actelion Pharmaceuticals Ltd composto, composição farmacêutica, e, uso de um composto
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
PT2674428T (pt) 2006-04-07 2016-07-14 Vertex Pharma Modeladores de transportadores de cassetes de ligação de atp
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
CN102850324A (zh) * 2006-08-07 2013-01-02 硬木药品公司 吲哚化合物
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
JP2013525371A (ja) 2010-04-22 2013-06-20 バーテックス ファーマシューティカルズ インコーポレイテッド シクロアルキルカルボキサミド−インドール化合物の製造方法
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
WO2012135027A2 (en) * 2011-03-25 2012-10-04 The Research Foundation Of State University Of New York Thiolactone antibiotics
HK1209318A1 (en) 2012-07-16 2016-04-01 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
HUE039062T2 (hu) 2014-04-15 2018-12-28 Vertex Pharma Gyógyszerészeti készítmények cisztás fibrózis transzmembrán konduktancia regulátor által mediált betegségek kezelésére
CN115785079B (zh) * 2022-11-28 2024-02-13 沈阳药科大学 4-(1h-吲哚-5-基)氨基呋喃-2(5h)-酮类化合物及其制备和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU714873B2 (en) * 1995-08-02 2000-01-13 Newcastle University Ventures Limited Benzimidazole compounds
CO4970714A1 (es) * 1997-09-05 2000-11-07 Boehringer Mannheim Gmbh Derivados ureido y tioureido de 4-amino-2(5h)-furanonas y 4-amino-2(5h) tiofenonas como agentes antitumorales
DE19814838C2 (de) 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
TR200003130T2 (tr) * 1998-04-28 2001-01-22 Arzneimittelwerk Dresden Gmbh Yeni hidroksiindoller, bunların fosfodiesteraz 4 inhibitörleri olarak kullanımları ve hazırlanmaları için işlemler

Also Published As

Publication number Publication date
IT1315267B1 (it) 2003-02-03
EP1244652B1 (en) 2005-08-24
ZA200204964B (en) 2004-01-29
US6753342B2 (en) 2004-06-22
SK285682B6 (sk) 2007-06-07
CA2395205A1 (en) 2001-07-05
NO20022976D0 (no) 2002-06-20
EA200200558A1 (ru) 2002-12-26
NO323312B1 (no) 2007-03-12
BR0016553A (pt) 2002-09-17
AU2170401A (en) 2001-07-09
JP2003519140A (ja) 2003-06-17
HUP0203524A2 (hu) 2003-03-28
ITMI992693A1 (it) 2001-06-23
AU776332B2 (en) 2004-09-02
NZ519689A (en) 2004-02-27
EA004925B1 (ru) 2004-10-28
KR20020063247A (ko) 2002-08-01
IL150329A (en) 2006-07-05
KR100795533B1 (ko) 2008-01-16
NO20022976L (no) 2002-06-20
PL356541A1 (en) 2004-06-28
WO2001047916A1 (en) 2001-07-05
IL150329A0 (en) 2002-12-01
MXPA02006217A (es) 2004-02-26
DE60022227T2 (de) 2006-06-22
CN1413205A (zh) 2003-04-23
CZ20022170A3 (cs) 2002-09-11
HUP0203524A3 (en) 2008-01-28
ES2246918T3 (es) 2006-03-01
ITMI992693A0 (it) 1999-12-23
EP1244652A1 (en) 2002-10-02
CN1250542C (zh) 2006-04-12
SK8962002A3 (en) 2002-11-06
DE60022227D1 (de) 2005-09-29
ATE302772T1 (de) 2005-09-15
US20030158153A1 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
TR200201613T2 (tr) Antitümör tesirli 2-(1H-indol-3-il)-2-okso asetamidler
DE69918422D1 (de) Phthalazinone pde iii/iv hemmer
NL350077I2 (nl) Cyprosulfamide
FI970246A0 (fi) Dihydrobentsofuraanit
TR199901653T2 (tr) Fitalazinonlar.
PT1109812E (pt) Pirrolobenzodiazepinas
DK1200418T3 (da) Nematodicide trifluorbutener
YU72002A (sh) Benzoilpirazoli i njihova primena u ulozi herbicida
NO20025590D0 (no) Fenylglycin-derivater
BG107220A (en) Antitumoral ecteinascudin derivatives
EE200000033A (et) Uudsed tetrasoolderivaadid
ATE258930T1 (de) Dihydrobenzifurane
ATE311389T1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
DK1377574T3 (da) 6-phenylbenzonaphtyridiner
SE9903290D0 (sv) Novel compounds
TR199901386T2 (tr) Imidazopiridazinler.
BG106937A (en) Novel indole derivatives
ATE413397T1 (de) Heterosubstituierte c7-taxanacetate als antitumormittel
TR200003203T2 (tr) Karboksaldehitin saflaştırılması
ATE213236T1 (de) Substituierte benzyloxyimino-verbindungen
BG105247A (en) N-substituted azabicycloheptane derivatives, production and use thereof
TR199801366T2 (tr) Izooksasefem türevleri.
ATE263560T1 (de) Neue verwendung von citreamicinen
PL373989A1 (en) Novel benzonaphthyridines
UA33865A (uk) Дикалієва сіль n-сукцин - dl-триптофану, що має антиангінальну та антигіпоксантну дію